David Rubin to Interleukin-23 Subunit p19
This is a "connection" page, showing publications David Rubin has written about Interleukin-23 Subunit p19.
Connection Strength
0.059
-
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 04; 11(4):284-298.
Score: 0.059